To date, no efficacious treatments for prion diseases are available in clinical settings.
1,2 Anti-PrP antibodies can delay scrapie after peripheral challenge of prions. 3, 4 However, this strategy does not target PrP Sc replication in the brain, and intracerebral delivery of anti-PrP C antibodies may be neurotoxic. 5 Active immunization strategies are meeting with little success most likely because endogenous PrP C induces robust immune tolerance. 6, 7 Transgenic expression of a soluble dimeric PrP, termed PrP-Fc 2 , affects prion propagation and scrapie pathogenesis by interfering with the buildup of PrP Sc . 8 The high solubility and stability of PrP-Fc 2 prompted us to explore its therapeutic potential. We therefore used lentiviral vectors 9 to investigate in a scrapie mouse model whether sustained intracerebral expression of PrP-Fc 2 inhibits prion replication.
Materials and Methods

Mice
Mouse lines tg550Stop, carrying a loxP-flanked transcription-termination cassette upstream of the open reading frame of PrPFc, and tg588 CMV , in which the transcriptiontermination cassette was eliminated, were described previously. 8 Mice carrying the Cre recombinase under the transcriptional control of the Nestin, glial fibrillary acidic protein (GFAP), or proteolipid protein (PLP) regulatory elements have been described elsewhere. 10 -12 tg550Stop ϫ PLP/Cre-ERT2, tg550Stop (but Cre-negative), and PLP/Cre-ERT2 (but tg550Stop-negative) littermates were treated with tamoxifen dissolved in a sunflower oil/ethanol (10:1) mixture at 10 mg/ml. Twice 1 mg of tamoxifen per day for 5 consecutive days was injected intraperitoneally, as described. 12 
Vector Production and Injection
PrPFc cDNA was cloned into the lentiviral vector pRRL.sin.cPPT.hCMV.GFP.Wpre 9 in place of GFP. Vectors stocks were generated as described 9 by co-trans-fection of 293T with pCMV-⌬R8.91, 13 pMD.G, 13 and pRRL.sin.cPPT.hCMV.PrPFc vectors. 293T-conditioned media were filtered and ultracentrifuged to concentrate the vector. 9 Particle content was measured by HIV-1 p24 antigen immunocapture. 9 HIV-1 p24 concentration was between 500 to 600 g/ml (corresponding to 100,000 infectious units per ng of p24). C57BL/6 mice were slowly injected with 5 l of the lentiviral preparations or phosphate-buffered saline (PBS) stereotaxically into the hippocampus or 30 l intracerebrally into the right telencephalic hemisphere. Integration of the transgene was detected by polymerase chain reaction (PCR) with standard conditions using primers amplifying the PrP and Fc regions (Table 1) .
Western Blot Analysis and NaPTA Precipitation
Sodium phosphotungstate precipitation and quantitative Western blot were performed as described. 8 Brain and spleen samples were digested for 30 minutes at 37°C with 50 g/ml and 20 g/ml of proteinase K, respectively. Antibody incubations were done in 1% Top-Block (Sigma-Aldrich Chemia GmbH, Buchs, Switzerland) in Tris-buffered saline Tween 20 with ICSM18 3 or POM1 14 for PrP and PrP-Fc 2 for 1 hour at room temperature or overnight at 4°C. The samples were analyzed with a VersaDoc digital imager (model 5000; Bio-Rad, Hercules, CA).
Bone Marrow (BM) Chimeric Mice
BM cells (5 ϫ 10 6 ) were isolated from tibiae and femurs, and injected into tail veins of 8-to 10-week-old recipients conditioned by whole-body irradiation (1100 rad). Several paradigms were generated: wt BM was injected into wt or tg588-irradiated mice, and tg588 BM was injected into wt or tg588-irradiated mice. The tg588 CMV line (for brevity tg588) was used in the BM reconstitution experiments because of the sixfold higher expression of PrPFc 2 in spleen in tg588 compared to tg550. 8 Eight weeks after grafting, reconstitution was assessed by enzymelined immunosorbent assay (ELISA) analysis of peripheral blood taken from the retro-orbital plexus of etheranesthetized mice.
ELISA Analysis
ELISA to detect PrP-Fc 2 was performed as described. 3, 4 Briefly, plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with monoclonal anti-PrP antibody ICSM 18, washed with PBS containing 0.1% (v/v) Tween 20 (PBST), and blocked with 5% bovine serum albumin (BSA). After washing, plates were incubated with 30 l of twofold serially diluted serum (1:20 prediluted) in PBST containing 1% BSA and then probed with horseradish peroxidase-conjugated goat anti-human IgG-Fc horseradish peroxidase (1:1000 dilution; Rockland Immunochemicals, Gilbertsville, PA). Plates were developed with 2,2Ј-azino-diethyl-benzothiazolinsulfonate, and optical density was measured at 405 nm. Titer was defined as the highest dilution showing an OD more than two times the technical background, which was calculated as the average of uncoated wells and wells incubated omitting serum. For detection of anti-human Fc and anti-GFP antibodies in serum of lentivirus-treated mice, the plates were coated with purified human Fc and GFP-His, 15 respectively. The antibodies from the serum were detected in the plates by using rabbit anti-mouse IgG ϩ A ϩ M (H ϩ L)-horseradish peroxidase conjugate (Zymed/Invitrogen AG, Basel, Switzerland).
Histopathology
Brains were fixed in 4% paraformaldehyde, paraffin-embedded, and cut into 2-m sections. Sections were stained with hematoxylin and eosin (H&E) and with anti-GFAP. 16 Histoblots were performed according to published protocols. 17 For immunohistochemistry, cryosections were fixed 5 minutes in paraformaldehyde, 2 
Prion Inoculations
Mice were inoculated intracerebrally or intraperitoneally with 3 ϫ 10 2 or 10 3 LD 50 infectious units of Rocky Mountain Laboratory strain (RML, passage 5) scrapie prions prepared as described. 8 Mice were sacrificed on the day of onset of terminal clinical signs of scrapie. Significance P values were derived by comparing mean survival (Student's t-test; two-tailed distribution, two-sample unequal variance). Survival data were plot by using GraphPad Prism 4.
Infectivity Bioassays with tga20 Mice
Assays were performed on 1% homogenates of brain or of spleen tissues as described. 18 Tissues were homogenized in 0.32 mol/L sucrose with a homogenizer and diluted 1:10 in 5% BSA in PBS. Supernatants (30 l) were inoculated intracerebrally into groups of three to four tga20 mice. 19 Infectivity titers were calculated as described. 20 
Scrapie Cell Assay in Endpoint Format (SCEPA)
For SCEPA, highly RML prion-susceptible neuroblastoma cells (subclone N2aPK1 21 ) were exposed to prion samples for 3 days in 96-well plates, and split three times 1:3 every 2 days, and three times 1:10 every 3 days. After reaching confluence, 25,000 cells from each well were filtered onto the membrane of white Immobilon P plate (Millipore, Billerica, MA) treated with PK, denatured, and individual infected (PrP Sc -positive) cells were detected by ELISA using antibody POM-1 to PrP. After reaching confluence, 25,000 cells from each well were processed as above. Wells were counted positive if the spot number was clearly exceeding background. From the proportion of negative to total wells the number of infectious tissue culture (TCI) units per aliquot was calculated by the Poisson equation as described previously. 21 The potency of the SCEPA is based on the finding that the proportion of infected cells, and with it the signal-to-background ratio, increases on average ϳ25% per day during culturing. The sensitivity of the assay can be further enhanced by increasing the number of replicate samples and the number of 1:10 splits.
Preparation of Cerebellar Granule Cells, Oligodendrocytes, and Astrocytes
Cerebellar granule neurons were prepared from 7-to 8-day-old mice as previously described. 22 Contamination with glial cells was Ͻ5%. Mixed glial cell cultures containing oligodendrocytes and astrocytes were produced from 1-day-old neonatal mice as described. 23, 24 Cultures were prepared with high-glucose Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and replenished on day 4 and every 3 to 4 days thereafter for 10 days, with Dulbecco's modified Eagle medium plus 10% heat-inactivated horse serum. Oligodendrocytes were purified from mixed glial cultures by differential detachment and negative selection of microglia by adherence to hydrophobic plastic. Purified oligodendrocytes were then plated onto glass or plastic culture chambers coated, respectively, with 100 g/ml or 10 g/ml poly-L-lysine, whereas astrocytes were kept in the same dish. Oligodendrocyte precursors were expanded with platelet-derived growth factor-and fibroblast growth factor-supplemented SATO medium for 2 days and subsequently differentiated with 1% horse serum-supplemented SATO medium for 3 days.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature. The cultures were permeabilized and blocked in PBS supplemented with 0.1% Triton X-100 and 10% fetal calf serum. Cells were then incubated with antibodies against neuronal-specific nuclear protein (NeuN, 1:50), glial fibrillary acidic protein (GFAP, 1:100; DAKO, Glostrup, Denmark), and myelinassociated glycoprotein (MAG; 1:100; Chemicon, Temecula, CA) diluted in 1% BSA in PBS at 4°C overnight. After washing, cells were incubated with goat anti-mouse secondary antibodies conjugated with Alexa 546 (1: 200; Molecular Probes, Eugene, OR) or with donkey anti-rabbit secondary antibodies conjugated with fluorescein isothiocyanate (1:50; Jackson Laboratory, Bar Harbor, ME). Nuclear staining was performed with DAPI.
Results
We generated a recombinant lentiviral vector transducing PrP-Fc 2 (henceforth termed PrPFc; Figure 1a) . In a first series of experiments we investigated whether PrPFc, when precisely targeted to a defined group of cells, would afford local protection. We therefore injected a relatively small amount of PrPFc (3 ϫ 10 8 infectious units in 5 l) into a group of five mice intrahippocampally under stereotaxic guidance. Controls were injected with PBS (n ϭ 5). One mouse from each group was sacrificed 6 months after virus injection to provide a first indication about disease progression. PrP-Fc 2 was detected by immunohistochemistry in the injected hippocampus, but not in the contralateral hemisphere (Figure 1b, top row) . Accordingly, lentiviral integration in the brain was demonstrated by PCR analysis (Figure 1c) . No adverse reac-tions were detected by conventional histology (Figure  1d ), nor by immunohistochemistry with various astroglial, microglial, and inflammatory markers (GFAP, CD11b, Iba-1; data not shown).
Twenty days after virus injection, four PrPFc-treated mice and four PBS controls were inoculated intracerebrally with 3 ϫ 10 2 LD 50 RML prions. All PBS-injected control animals succumbed to disease [177 Ϯ 8 days postintracerebral prion inoculation (dpi)], whereas none of the PrPFc-treated animals showed clinical signs at 177 dpi (Figure 1f) . One clinically unaffected PrPFctreated mouse was sacrificed at 170 dpi and analyzed for the presence of PrP Sc by histoblotting. Whereas PBStreated animals showed massive PrP Sc accumulation, the PrPFc-injected mouse showed markedly reduced accumulation of PrP Sc in the injected hippocampus. Importantly, ipsilateral reduction in PrP Sc signal intensity extended well beyond the track of the stereotaxic needle, suggesting that PrPFc exerts long-range antiprion effects. In the contralateral hemisphere, however, PrP Sc Sc signals were saturated in the contralateral hemisphere and in a PBS-treated brain. f: Survival plots displaying the incubation time until development of terminal scrapie in PBS-and PrPFc-treated mice after intracerebral challenge. Median disease onset was delayed by 36 days in intrahippocampally PrPFc-treated mice. LTR, long terminal repeats; CMV, cytomegalovirus; SD, splice donor; SA, splice acceptor; ⌿, packaging sequence; GA, 5Ј portion of gag gene with truncated reading frame including extended packaging signal; RRE, rev response element (RRE); cPPT, central polypurine tract; WPRE, posttranscriptional regulatory element from the genome of the woodchuck hepatitis virus.
deposition was indistinguishable from that of PBS-treated controls (Figure 1e ). Histological analysis failed to reveal any vacuolation and astrogliosis in the ipsilateral hippocampus (Figure 1b, middle and bottom rows) . The contralateral side presented with rather strong vacuolation and astrogliosis, although the corresponding region of a terminally sick PBS-treated animal may have been more strongly affected (Figure 1b , middle and bottom rows). PrPFc-injected mice succumbed to disease at 213 Ϯ 6 dpi (Figure 1f) , which is remarkable, considering substantial vacuolation and PrP Sc deposits detected in the contralateral side of the PrPFc-injected mice sacrificed for analysis at 170 dpi (see above; Figure 1b , middle row; and Figure 1e, bottom row) . Therefore, a single Sc accumulation in the tested PrPFc-treated brain was 0.03% of the tested PBS-treated brain. To reach a comparable intensity level for Western blot quantification, control samples were diluted linearly up to 32 times, whereas for PrPFc-treated brains, PrP Sc was concentrated by NaPTA precipitation from 125-or 250-fold more starting material than was used directly for Western blot in the case of PBS-treated mouse, lane 1. e: Prion infectivity, determined in the brain of one PrPFc-treated animal by the scrapie cell assay in endpoint format (SCEPA), was reduced by 4.2 log TCl/g tissue compared to PBS-treated animals. f: Survival of scrapie-infected mice treated with PBS or PrPFc. Whereas PBS-treated mice (n ϭ 4) succumbed to disease at 175 Ϯ 5 dpi, PrPFc-treated animals (n ϭ 3) had an extended survival of 72 days (247 Ϯ 8 dpi). Vol. 172, No. 5 unilateral hippocampal injection sufficed to delay onset of disease by 36 days (P Ͻ 0.01) as compared to PBSinjected controls.
Antiprion Prophylaxis by
The above results, along with the observation that the antiprion action of PrP-Fc 2 is dose-dependent in transgenic mice, 8, 25 encouraged us to explore whether nonstereotaxic delivery of a larger number of PrPFc particles would enhance protection. We injected 30 l of PrPFc (1.5 ϫ 10 9 infectious units) intracerebrally into the right telencephalic hemisphere of mice (n ϭ 4), and inoculated them with 3 ϫ 10 2 LD 50 RML prions intracerebrally 20 days later. Six months after virus injection, immunoblot analysis revealed sustained PrP-Fc 2 expression in brains of PrPFc-treated mice (Figure 2a) .
We sacrificed one presymptomatic PrPFc-treated mouse and two terminally sick PBS-treated mice at 171 dpi to estimate prion pathogenesis at this experimental paradigm. Profound histopathological changes were identified in PBS-treated brains (Figure 2b ). In contrast, the PrPFc-treated brain displayed no spongiform changes ipsi-or contralaterally. Astrogliosis, estimated by GFAP immunoreactivity, was similar to age-matched uninfected mice (Figure 2b ).
Brain, spinal cord, and spleen homogenates were subjected to proteinase K (PK) digestion and analyzed for accumulation of PrP Sc by Western blot analysis. Surprisingly, whereas wild-type (wt) animals showed extensive buildup of PrP Sc , no PrP Sc was detectable in the brain of the PrPFc-treated animal and only traces thereof in the spinal cord (Figure 2c) . Conversely, spleens from all animals showed similar accumulation of PrP Sc , suggesting that protection was restricted to the central nervous system (CNS) (Figure 2c ). To increase the sensitivity of PrP Sc detection, we concentrated PrP Sc by differential precipitation with sodium phosphotungstic acid (NaPTA). Quantitative Western blot analysis 4 showed that PrP Sc accumulation in PrPFc-treated brain was 0.03% of PBStreated brain. To reach a comparable intensity level for Western blot quantification, control samples were diluted linearly up to 32 times, whereas for PrPFc-treated brains, PrP Sc was concentrated by NaPTA precipitation from 125-or 250-fold more starting material than is was used directly for Western blot in the case of PBS-treated mouse, lane 1 (Figure 2d ). Prion infectivity titers determined by end-point scrapie cell assay 21 were similar in spleens of PBS-and PrPFc-treated mice [4.1 and 4.6 log infectious tissue culture units (TCI U)/g tissue, respectively, Figure 2e ]. In contrast, prion titers in control brains (n ϭ 2) reached 7.6 log TCI U/g tissue, but only 3.4 log TCI U/g tissue in the treated animal (Figure 2e ). Typical progressive signs of scrapie, including ataxia and kyphosis, led to terminal disease in all PBS-treated mice by 175 Ϯ 5 dpi (n ϭ 4). In contrast, PrPFc-treated animals succumbed to prion disease at 247 Ϯ 8 dpi (n ϭ 3), suggesting remarkable resistance to the disease (72 days) and extending their lifespan by more than 40% (Figure 2f) . Therefore, single-dose gene transfer of PrPFc provides very potent protection against prion disease, and suppresses prion replication by Ͼ10,000-fold.
Next, we tested whether PrP-Fc 2 might afford postexposure prophylaxis. Mice were inoculated with 3 ϫ 10 2 LD 50 RML prions intracerebrally and, 30 days later, intracerebrally treated with PrPFc (1.5 ϫ 10 9 IU; n ϭ 7). Control animals injected with GFPFc (0.8 ϫ 10 9 IU; n ϭ 6) succumbed to scrapie at 163 Ϯ 4 dpi, whereas PrPFc-treated animals survived 188 Ϯ 11 days (P Ͻ 0.01) (Figure 3a) . Terminally sick mice from both groups showed similar PrP Sc accumulation in their brains (data not shown). We then administered PrPFc at 121 dpi, when scrapie-induced brain damage is already evident by histology (A.A., unpublished data). GFPFc (n ϭ 7)-and PrPFc (n ϭ 8)-treated animals succumbed with similar incubation times (197 Ϯ 17 dpi and 197 Ϯ 9 dpi, respectively), suggesting that treatment at this stage is ineffective (Figure 3b) . Importantly, we detected by ELISA anti-GFP antibodies in serum of the GFPFctreated mice and anti-human Fc antibodies in serum of the GFPFc-treated mice and PrPFc-treated mice (data not shown). This indicates that secreted GFP-Fc 2 and PrP-Fc 2 , both fused to human Fc, crossed the bloodbrain-barrier, and were processed by the murine immune system as immunogens. Induction of the transgene-specific antibodies may affect prion propagation. It has been reported that chronic activation of the immune system in the periphery facilitates prion pathogenesis. 26 -28 This may also explain faster onset of disease seen for the groups treated with the same lentivirus at 30 dpi compared to 121 dpi. (Figure 3, a and b) . We then sought to determine whether peripherally expressed PrP-Fc 2 contributes to the antiprion effect. We used transplantation of genetically modified BM progenitors, because this technique may represent a gene therapy vehicle. BM of PrP-Fc 2 -expressing mice (tg588 CMV ) 8 or of wt mice was transferred to wt or to tg588 CMV mice. Eight weeks after BM grafting, the concentration of PrP-Fc 2 was assessed in peripheral blood by ELISA (Figure 4a ). Blood PrP-Fc 2 concentrations of tg588 CMV mice that had received wt BM approached those of tg588
CMV mice and were four to six times higher than those of wt mice reconstituted with tg588 CMV BM, indicating that circulating PrP-Fc 2 is mainly contributed by nonhematopoietic radioresistant cells (Figure 4a) .
Twelve weeks after reconstitution, chimeric mice were challenged intraperitoneally with 10 3 LD 50 RML prions. At 50 dpi, immunoblot analysis showed that PrP Sc accumulation was reduced in spleens of tg588 CMV 3wt (n ϭ 2) and wt3tg588 CMV (n ϭ 2) compared to wt3wt mice (Figure 4b) . Accordingly, splenic prion titers in tg588 CMV 3wt (n ϭ 2) were 1.2 log lower than wt3wt (n ϭ 2) (Figure 4c ) and wt3tg588 spleen (n ϭ 1) showed no detectable infectivity (Figure 4c ). Wt3wt mice (n ϭ 3) and tg588
CMV 3wt mice (n ϭ 3) developed scrapie with identical latency (232 Ϯ 7 dpi and 232 Ϯ 6 dpi, respectively), whereas wt3tg588 CMV (n ϭ 4) and tg588 CMV 3tg588 CMV (n ϭ 2) were affected later (300 Ϯ 21 dpi and 337 Ϯ 25 dpi, respectively) (Figure 4d ). These results indicate that PrP-Fc 2 -expressing hematopoietic cells antagonized PrP Sc accumulation and prion replication, yet failed to modify the clinical course of prion disease.
Replication-defective lentiviral vectors are not expected to spread throughout the brain after a single unilocular injection. 29 PrP-Fc 2 may therefore owe its potent antiprion efficacy to secretion and extracellular spread. This scenario assumes that PrP-Fc 2 would be capable of antagonizing PrP Sc deposition and prion replication in a noncell autonomous manner. We tested this hypothesis in tg550Stop mice, which bear a PrP-Fc 2 transgene preceded by a loxP-flanked transcriptional stop cassette.
8 tg550Stop mice 8 were bred to nestin/ Cre 10 (tg550 Nestin ), GFAP/Cre 11 (tg550 GFAP ), or PLP/Cre-ERT2 12 (tg550 PLP ) recombinator mice, activating expression of PrP-Fc 2 in the entire CNS, in astrocytes, or in oligodendrocytes, respectively. Before prion inoculation, tg550Stop ϫ PLP/Cre-ERT2, tg550Stop (but Cre-negative), and PLP/Cre-ERT2 (but tg550Stop-negative) littermates were treated daily with 2 mg of tamoxifen intraperitoneally for 5 days to activate Cre recombination.
12
Figure 4. Effects of hematopoietically expressed PrP-Fc 2 . a: PrP-Fc 2 titers (relative units) in blood of chimeric mice. tg5883wt reconstituted mice showed weaker PrP-Fc 2 expression than tg588 mice. b: Fifty days after RML prion inoculation, spleens from tg5883wt and wt3 tg588 showed decreased accumulation of PrP Sc compared to wt3wt spleens. c: Infectivity titer of wt3 tg588 (n ϭ 1) was below detectability and those of tg5883wt (n ϭ 2) were 1.2 log lower than wt3wt (n ϭ 2, average is represented) controls. d: wt3wt and tg5883wt reconstituted mice succumbed to scrapie at the same stage, whereas wt3 tg588 and tg5883 tg588 mice were retarded.
Restriction of transgene expression to the specified cell populations was tested on primary cell cultures of cerebellar granule neurons, astrocytes, and oligodendrocytes from tg550
Nestin , tg550 GFAP , and tg550 PLP mice. Purity in these primary cultures was typically Ͼ95%, as determined by specific cellular marker stains (see Supplemental Figure S1 at http://ajp.amjpathol.org). Cells were lysed and subjected to Western blot analysis for PrP-Fc 2 (see Supplemental Figure S2 at http://ajp.amjpathol. org). Expression of PrP-Fc 2 was relatively weak in tg550 PLP oligodendrocytes (maybe because the Prnp promoter is weakly active in oligodendrocytes 30, 31 ), but undetectable in neurons and astrocytes (see Supplemental Figure S2 at GFAP mice showed delayed disease after intracerebral inoculation (151 and 65 days, respectively; P Ͻ 0.01) ( Figure 5 , a and c) and after intraperitoneal inoculation (90 and 65 days, respectively; P Ͻ 0.01) ( Figure 5 , b and d). Astrocytes have been shown to be competent for prion replication, 32 although the toxicity of astrocytic PrP Sc to neurons is somewhat controversial. 33, 34 To determine whether PrP-Fc 2 exerts its antiprion effect when produced by cells resistant to prion infection, we inoculated tg550 PLP , which expressed PrP-Fc 2 selectively in oligodendrocytes (see Supplemental Figure S2 at http://ajp.amjpathol.org) and Schwann cells. 12 Transgenic mice expressing PrP under the control of the myelin basic protein-promoter are resistant to prion infection, suggesting that oligodendrocytes and Schwann cells do not support cell-autonomous prion replication and neural spread of prions. 31 We found that tg550 PLP mice (n ϭ 8), which expressed low amounts of PrP-Fc 2 , showed delayed disease over tamoxifen-treated tg550Stop and PLP/Cre-ERT2 mice. The delay was 35 days (P Ͻ 0.01) after intracerebral inoculation (Figure 5e ) and 50 days (P Ͻ 0.01) after intraperitoneal inoculation (Figure 5f ). confirming the similar prion replication rate in spleens of each genotype (see Supplemental Table S1 (Figure 5g ). In contrast, tg550 Nestin , tg550 GFAP , and tg550 PLP sacrificed at the time at which wt controls mice had developed terminal scrapie, showed markedly reduced PrP Sc accumulation (Figure 5g ). With the caveat that Western blot analyses are only semiquantitative, this suggests that PrP Sc deposition is counteracted even when PrP-Fc 2 is expressed by CNS cells unable to replicate prions.
Next, we analyzed neuropathological changes during the course of the disease. At terminal stage (181/183/224 dpi), all control animals showed pathological evidence of neuroinvasive CNS scrapie infection to a similar extent (Figure 5h and data not shown). At these time points, tg550
Nestin mice showed only weak astrogliosis, vacuolation, and PrP Sc deposition (Figure 5h and data not shown), whereas in tg550 GFAP and tg550 PLP mice, neuropathological changes were more advanced, as reflected by astrocytosis, PrP Sc deposition, and spongiform degeneration (Figure 5h and data not shown), but were still reduced in comparison to wt sick mice. Therefore, PrP-Fc 2 not only delays PrP Sc accumulation in the brain, but also retards histopathological changes. The entirety of the above results strongly suggests that PrP-Fc 2 delays PrP Sc accumulation and prion disease in a noncell autonomous manner.
Discussion
We have explored in vivo gene therapy in a mouse model of prion disease. Our approach resulted in sustained expression of a soluble prion antagonist in the brain, impaired replication of disease-associated PrP Sc , effective neuropathological protection, and delayed disease progression. Even though lentiviral transduction is limited to the site of injection, 29 PrP Sc accumulation was decreased in most of the brain. The most plausible interpretation is that secreted PrP-Fc 2 was released into the cerebrospinal fluid, where it antagonized PrP Sc replication noncell autonomously, as suggested in a previous report. 8 Why was PrPFc less efficient to delay prion pathogenesis when delivered during disease progression? Transgene expression may take 4 to 6 weeks before reaching its maximum. 35 Therefore, after injection at 30 dpi, high expression of PrP-Fc 2 was achieved in the brain ϳ60 to 75 dpi, when prion infectivity and PrP Sc have already colonized the brain. Indeed, we detected PrP Sc in the brain by Western blot as early as 58 dpi (data not shown). Because there is a competitive interaction between PrP-Fc 2 and PrP C for PrP Sc , 8 the presence of substoichiometric PrP-Fc 2 may not be sufficient to efficiently prevent PrP Sc formation and may only weakly slow down its accumulation.
Direct gene delivery of a soluble prion antagonist into the CNS by lentiviral vectors may be an effective strategy against prion diseases. In contrast, almost all previous therapeutic interventions only showed benefits after extracerebral injection, probably reflecting the difficulty of most of the drugs to cross the blood-brain barrier. 3,36 -38 Because variant Creutzfeld-Jakob disease can be diagnosed before death on lymphoid tissues 39 and patients may display extraneural PrP Sc long before neuroinvasion, 40 gene delivery of prion antagonists directly in the brain may be sufficient to block PrP Sc before it has already colonized the CNS. In this context, our findings may provide a promising new approach to prion therapeutics.
